HER2-negative means that cancer cells have little to no HER2 protein on their surface. HER2 is a protein that promotes cell growth, and when cancer cells don’t overproduce it, the tumor generally behaves less aggressively than HER2-positive cancers. About 80% of all breast cancers are HER2-negative, making it the most common classification. Understanding your HER2 status matters because it directly shapes which treatments will and won’t work.
What HER2 Does in the Body
HER2 (Human Epidermal Growth Factor Receptor 2) is a protein that sits on the surface of cells and sends signals telling them to grow and divide. In normal tissue, HER2 helps regulate healthy cell turnover. Problems arise when a cell makes too many copies of the HER2 gene, flooding its surface with excess protein. Those extra receptors pair up and fire off constant growth signals, pushing cells to multiply out of control.
The HER2 protein is especially potent when it pairs with a related protein called HER3. That pairing activates a powerful internal pathway that acts as a master switch for cell growth and survival. HER2 also interferes with natural braking mechanisms that normally stop cells from dividing too fast. When HER2 is overproduced, both of these effects combine to fuel aggressive tumor growth.
In a HER2-negative tumor, the cells aren’t overproducing this protein. Growth signals still exist (cancer is still cancer), but they’re driven by other mechanisms rather than by a flood of HER2.
How HER2 Status Is Tested
Pathologists determine HER2 status using a tissue sample from the tumor, typically collected during a biopsy. The first test is immunohistochemistry (IHC), which stains cells to measure how much HER2 protein is present. Results come back on a scale from 0 to 3+:
- IHC 0: No detectable HER2 protein. Definitively negative.
- IHC 1+: Faint, low-level protein expression. Still classified as negative.
- IHC 2+: Moderate expression. This score is considered equivocal, meaning it’s unclear, and requires a second test.
- IHC 3+: High protein expression. HER2-positive.
When the result is 2+, a follow-up test called FISH (fluorescence in situ hybridization) checks whether the HER2 gene itself is amplified. If FISH shows no gene amplification, the tumor is classified as HER2-negative despite the moderate protein staining. These criteria come from the ASCO/CAP guidelines, which were most recently updated in 2023.
The HER2-Low Category
Until recently, HER2 status was a simple yes or no. That changed after clinical trials showed that a newer class of drugs called antibody-drug conjugates could benefit patients whose tumors express small amounts of HER2, even though those tumors were traditionally labeled negative.
This led to a new subcategory: HER2-low, defined as an IHC score of 1+ or an IHC score of 2+ with no gene amplification on FISH. These tumors still fall under the broader HER2-negative umbrella, but distinguishing them from truly HER2-zero tumors now has treatment implications, particularly for metastatic breast cancer. Pathology reports increasingly include this distinction.
There’s even a finer slice being recognized. Some tumors scored as IHC 0 show faint, incomplete membrane staining in a small percentage of cells, below the threshold for 1+. These are being called HER2-ultralow, and researchers are studying whether they too might respond to antibody-drug conjugates. Tumors with absolutely no HER2 staining are termed HER2-null.
How Common HER2-Negative Breast Cancer Is
HER2-negative breast cancer is far more common than HER2-positive. According to National Cancer Institute data from 2018 to 2022, roughly 70% of female breast cancers are hormone receptor-positive and HER2-negative. Another 11% are both hormone receptor-negative and HER2-negative (also known as triple-negative breast cancer). Combined, about 80% of breast cancers fall into the HER2-negative category.
What It Means for Tumor Behavior
HER2-negative tumors are generally less aggressive than their HER2-positive counterparts. Without the excess growth signaling driven by HER2 overexpression, these cancers tend to grow more slowly. HER2-positive tumors, by contrast, are associated with faster spread and higher rates of metastasis to organs like the liver and lungs.
HER2 status also matters in other cancers, particularly stomach (gastric) cancer. In advanced gastric cancer, HER2-positive patients had a median overall survival of about 15 months compared to roughly 9 months for HER2-negative patients in one retrospective study. The survival difference partly reflects the availability of HER2-targeted therapies for positive patients rather than HER2-negative disease being inherently more lethal.
Treatment for HER2-Negative Breast Cancer
Because HER2-negative cancer cells don’t rely on HER2 for growth, traditional HER2-targeted therapies won’t work. Treatment depends heavily on whether the tumor is also hormone receptor-positive or negative.
Hormone Receptor-Positive, HER2-Negative
This is the largest subtype, and hormone-blocking therapy is the standard first-line approach, even when cancer has spread to other organs. These drugs starve the tumor by cutting off the hormonal signals it depends on. Options include medications that block estrogen receptors, drugs that reduce estrogen production, and agents that break down the estrogen receptor entirely. Guidelines recommend hormone therapy over chemotherapy as the starting treatment for most patients because it’s effective and causes fewer side effects.
Drugs that block a protein involved in cell division (CDK4/6 inhibitors) are now commonly added alongside hormone therapy and have significantly extended the time before disease progresses. This combination allows many patients to delay chemotherapy, sometimes for years.
Triple-Negative Breast Cancer
When a tumor is both hormone receptor-negative and HER2-negative, it lacks the most common therapeutic targets. Chemotherapy remains the backbone of treatment, typically given as one drug at a time rather than in combination, rotating to a new agent when the current one stops working. Platinum-based chemotherapy may be considered, particularly for patients who carry BRCA gene mutations. Immunotherapy has also entered the picture for some triple-negative patients.
The Role of Antibody-Drug Conjugates
For patients with HER2-low metastatic breast cancer, antibody-drug conjugates represent a meaningful shift. These drugs attach a chemotherapy payload to an antibody that seeks out even low levels of HER2 protein on cancer cells. In the landmark DESTINY-Breast04 trial, this approach improved survival for HER2-low patients. This is precisely why the distinction between HER2-low and HER2-zero now matters in pathology reports.
HER2 Status Can Change Over Time
One underappreciated fact is that HER2 status isn’t always permanent. Studies have found discrepancies between the HER2 status of the original tumor and cancer that later spreads to other sites in roughly 29 to 49% of cases. One study of 201 early breast cancer patients found a 44% discordance rate between primary tumors and disseminated tumor cells.
This has real clinical consequences. Patients whose cancer shifted from HER2-negative in the primary tumor to HER2-positive in disseminated cells had worse outcomes, with more than double the risk of distant recurrence compared to patients whose status stayed consistent. For this reason, retesting HER2 status when cancer recurs or spreads is important, as the result could open up new treatment options that weren’t relevant at the time of the original diagnosis.